2nd Global HIV Clinical Forum – Presentations

  Session 1: Basic Principles
Basic Science of Integrase Inhibitors - Recent Advances
Dr. Francois Clavel, MD

Hôpital Saint-Louis, Paris, France
Resistance Characteristics of Integrase Inhibitors
Dr. Charlotte Charpentier, PharmD, PhD

Hôpital Bichat-Claude Bernard, Paris, France
Clinical Case - Transmitted/Acquired Resistance Related
Dr. Michelle Moorhouse, MBBCh

Wits RHI, Johannesburg, South Africa
  Session 2: Pharmacology and Global Implementation
Potential role of Integrase Inhibitors in resource-limited settings
Dr. Gary Maartens, MD

University of Cape Town, Cape Town, South Africa
Clinical Pharmacology related considerations
Dr. David Back, PhD

University of Liverpool, Liverpool, United Kingdom
  Session 3: Challenging Populations
Optimal Use of Integrase Inhibitors in Women
Dr. Sharon Walmsley, MSc, MD, FRCPC

University of Toronto, Toronto, Canada
Pediatric use of Integrase Inhibitors
Dr. Mark Cotton, MD

Stellenbosch University, Tygerberg, South Africa
  Abstract Presentations
 Clinical case of transmitted resistance to HIV Integrase Inhibitors
Dr. Carmen María González Domenech, Spain
 Mutations to Integrase inhibitors in real life
Dr. Isabel Viciana Ramos, Spain
 Dolutegravir monotherapy in HIV-infected naive patients with <100,000 copies/ml HIV-RNA load: a long-term follow-up.
Dr. Massimiliano Lanzafame, Italy
  Session 4: Clinical Utility of Integrase Inhibitors
The Role of Integrase Inhibitors during HIV prevention
Dr. Pep Coll, MD

Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Clinical Case -Reduced Drug Regimen
Dr. Pedro Cahn, MD, PhD

Fundación Huésped, Buenos Aires, Argentina
Optimizing Clinical Utility of Integrase Inhibitors
Dr. Anton Pozniak, MD, FRCP

Chelsea and Westminster Hospital, London, United Kingdom